Visit the Think Differently About Relief Web site and potentially save your patients up to $40 on prescriptions for SINGULAIR.
Up to $40 in Savings for Patients With Allergic Rhinitis
Be a part of the program. Provide a prescription for SINGULAIR, and a Think Differently About Relief patient brochure with savings card. Then, take advantage of the helpful educational resources for you and your staff.
Get program details and resources.Leukotrienes Contribute to Allergic Rhinitis Symptoms
Leukotrienes are associated with common early-phase response symptoms, such as sneezing, nasal itching, and rhinorrhea. They are also associated with late-phase allergic reactions such as congestion and rhinorrhea.
Watch this movie to see the important role of leukotrienes in allergic rhinitis.Reach for a Different Class of Therapy
SINGULAIR is not an antihistamine, not a steroid. Try SINGULAIR first. It is a once-daily oral tablet that helps relieve the symptoms of seasonal and year-round allergic rhinitis.
Give your patients proven efficacy without adjunctive therapy.Important Information
SINGULAIR is indicated for relief of symptoms of allergic rhinitis (seasonal allergic rhinitis in adults and children aged 2 years and older and perennial allergic rhinitis in adults and children aged 6 months and older).
In clinical trials, SINGULAIR was generally well tolerated, with a safety profile similar to that of placebo. Adverse events varied by age. The most commonly reported adverse events, occurring at a frequency of ≥1% and at an incidence greater than placebo, regardless of causality assessment, were sinusitis, upper respiratory infection, sinus headache, cough, epistaxis, headache, otitis media, pharyngitis, and increased ALT.
SINGULAIR is contraindicated in patients with hypersensitivity to any component of this product.
References: 1. Wang D, Clement P, Smitz J, De Waele M, Derde M-P. Correlations between complaints, inflammatory cells and mediator concentrations in nasal secretions after nasal allergen challenge and during natural allergen exposure. Int Arch Allergy Immunol. 1995:106:278–285. 2. Dykewicz MS, Fineman S, Skoner DP, et al; for Joint Council on Allergy, Asthma & Immunology. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 1998:81:478–518. 3. Bousquet J, van Cauwenberge P, Khaltaev N, et al; and ARIA Workshop Group. Co-morbidity and complications. J Allergy Clin Immunol. 2001;108(suppl):S198–S207.
This site is intended only for health care professionals of the United States, its territories, and Puerto Rico.
SINGULAIR and MerckServices are registered trademarks of Merck & Co., Inc. MerckProductServices is a trademark of Merck & Co., Inc.
20752407(1)-01/08-SNG
For general information and other services for physicians
